HORMAD1 Gene: Potential New Target for Triple Negative Breast Cancer Treatment

A gene typically associated with reproduction may offer a new therapeutic target for an aggressive form of breast cancer, according to research published this week in Nature Communications. Scientists have identified a potential weakness in triple-negative breast cancer cells linked to the HORMAD1 gene, opening avenues for the development of more effective treatments.

Understanding Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) accounts for approximately 15% of all breast cancer diagnoses. Unlike other types of breast cancer, TNBC cells lack receptors for estrogen, progesterone, and HER2, meaning standard hormone therapies and HER2-targeted drugs are ineffective. This often leads to more aggressive disease progression and limited treatment options. TNBC is also more prevalent in certain populations, including women with inherited BRCA gene mutations, those under 40, and Black women, according to Breast Cancer Now.

The Role of HORMAD1: From Reproduction to Cancer

The HORMAD1 gene is normally active only in reproductive cells – the ovaries and testes – where it plays a crucial role in ensuring accurate genetic information transfer during sperm and egg formation. However, researchers at the Institute of Cancer Research, London, and King’s College London, discovered that HORMAD1 becomes abnormally activated in around 60% of triple-negative breast cancers. The study, funded by Breast Cancer Now, reveals that this misplaced activation disrupts a key safety mechanism within cancer cells.

Specifically, the activation of HORMAD1 leads to errors in DNA replication as cancer cells divide. While these errors can fuel cancer growth and resistance to treatment, the researchers found that this disruption also represents a vulnerability that could be exploited therapeutically. The team identified a series of events and key proteins involved in this process, providing potential targets for new drugs.

Identifying Potential Drug Candidates

The research team has already identified several existing cancer drugs currently under investigation that show promise in targeting TNBC cells with active HORMAD1. These include Aurora B, MPS1, and BUB1 inhibitors. Notably, Aurora B inhibitors demonstrated a reduction in tumor growth in laboratory settings. As reported by OncoDaily, this suggests a potential pathway for repurposing existing medications to combat this challenging cancer subtype.

What are Aurora B, MPS1, and BUB1 inhibitors?

These are classes of drugs designed to interfere with cell division. Cancer cells divide rapidly, making them particularly vulnerable to drugs that disrupt this process. Aurora B, MPS1, and BUB1 are all proteins involved in ensuring accurate chromosome segregation during cell division. Inhibiting these proteins can lead to errors in chromosome distribution, ultimately halting cancer cell growth.

Study Details and Limitations

The findings, published in Nature Communications on February 17, 2026, are based on laboratory studies of breast cancer cells. While promising, it’s vital to note that these results have not yet been tested in clinical trials with patients. The study’s strength lies in identifying a previously unknown vulnerability in TNBC, but further research is needed to confirm these findings and assess the safety and efficacy of targeting HORMAD1 in humans. The research team acknowledges that the study focused on specific cell lines and may not fully represent the diversity of TNBC tumors.

What Which means for Patients

This research does not immediately change treatment recommendations for patients with triple-negative breast cancer. However, it offers a crucial step forward in understanding the disease and developing more targeted therapies. The identification of HORMAD1 as a potential target provides a new focus for drug development and could eventually lead to personalized treatment strategies based on a patient’s tumor characteristics. It’s important to remember that TNBC is a complex disease, and a single “magic bullet” is unlikely. The goal is to develop combinations of therapies that effectively target multiple vulnerabilities within cancer cells.

The Path Forward: From Lab to Clinic

The next phase of research will focus on identifying and testing the most effective drugs or drug combinations against TNBC cells with an active HORMAD1 gene. Researchers will prioritize safety and efficacy as they move towards clinical trials. This process typically involves several stages, including preclinical studies, Phase 1 trials (assessing safety), Phase 2 trials (assessing efficacy and dosage), and Phase 3 trials (comparing the new treatment to standard care). The timeline for bringing a new treatment to market can be several years, even with promising early results.

Professor Andrew Tutt, Director of the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, emphasized the early stage of the research, stating that it “offers an important step forward in understanding triple negative breast cancer and opens the door for the development of new treatments.”

Ongoing Surveillance and Research: Researchers will continue to monitor the prevalence of HORMAD1 activation in TNBC tumors and investigate potential biomarkers that could predict which patients are most likely to benefit from HORMAD1-targeted therapies.